Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617053 | 1.00 | LTA4H (0.55) | LTA4HCRBNDDB1ALDH1A1CHRM2 | |
| SCHEMBL22291300 | 0.88 | CRBN (0.58) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23729682 | 0.87 | CRBN (0.55) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30058706 | 0.87 | CRBN (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23705491 | 0.87 | CRBN (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23705600 | 0.86 | CRBN (0.56) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL28989024 | 0.86 | CRBN (0.52) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Formic Acid SCHEMBL23705562 | 0.86 | CRBN (0.53) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23705611 | 0.85 | CRBN (0.55) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30068455 | 0.85 | CRBN (0.54) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116867785-A | Compounds and uses thereof | 福宏治疗公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115666575-A | Compound and use thereof | 福宏治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4097096-A2 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115335373-A | Compound and use thereof | 福宏治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | LTA4H 3944/4885CRBN 179/4885DDB1 987/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | LTA4H 3786/4885CRBN 163/4885DDB1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.